Neurosense Therapeutics Ltd is trading 8% up at $0.81 in a relief rally following a multi-session slide and broader risk-off pressure on small-cap biotech stocks.
- The move comes despite a lack of fresh company-specific headlines or regulatory filings this morning, suggesting speculative buying in the thinly traded micro-cap.
- Broader U.S. indices are trending higher today, providing a supportive environment for risk appetite across the biotech sector.
- The stock is recovering from recent downward pressure as investors reassess positions after last week's volatility.